Nurix Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Arthur T. Sands
- Full Time Employees
- 286
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1700 Owens Street San Francisco CA United States of America 94158
- IPO Date
- Jul 24, 2020
- CIK
- 0001549595
- Website
- nurixtx.com
- Similar Companies
- Business
- Nurix Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics that modulate the ubiquitin proteasome system to treat human diseases. The company’s main products and services include research and development of targeted protein modulation therapies, primarily in oncology and immunology; proprietary E3 ligase-based drug discovery platforms; and pipeline assets such as clinical and preclinical drug candidates focused on various cancers and immune diseases. Nurix operates primarily in the United States, with its headquarters located in San Francisco, California, and it serves global markets through collaborations and partnerships. Founded in 2009, Nurix Therapeutics leverages its proprietary platform technologies to develop orally bioavailable small molecule drugs that degrade or inhibit proteins involved in disease pathways. Its core product categories encompass ubiquitin ligase modulators, molecular glues, and protein degraders designed to target otherwise undruggable proteins. In the last 1-2 years, Nurix has made significant strategic moves, including partnerships with major pharmaceutical companies for drug discovery collaboration, expansion of its clinical pipeline with the advancement of novel candidates into clinical trials, and increased investment in proprietary platform enhancements. The company has also focused on broadening its therapeutic areas and geographic reach through new licensing deals and research collaborations. These initiatives reflect Nurix’s strategy to accelerate the development of innovative therapies and expand its commercial potential. Nurix claims a strong position within the biotechnology industry, targeting oncology and immunology patient populations with unmet medical needs. It maintains several research collaborations and strategic alliances globally to further its drug discovery and development programs. The company remains independent, publicly traded under the ticker NRIX, and continues to build on its foundational science and robust pipeline capabilities.
Nurix Therapeutics Deal With Roche Is Worth Betting On
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
Nurix Therapeutics Stock Pops on Roche Partnership
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress